Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactiplantibacillus plantarum GMNL-661
- Development stage
- Preclinical
- Lead developer
- GenMont Biotech
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
GMNL-661 is a probiotic strain of *Lactiplantibacillus plantarum* (formerly *Lactobacillus plantarum*) developed by GenMont Biotech Incorporation. Administered orally in capsule or sachet form, it is intended to support gut health and gastrointestinal wellness. The strain's mechanism of action involves modulating the gut microbiota, enhancing the integrity of the intestinal barrier, and reducing gut inflammation. Preclinical research in murine models has demonstrated its potential in alleviating *Clostridioides difficile* infection (CDI) by reconfiguring the intestinal microbiome to increase the abundance of beneficial bacteria while suppressing pathogens. The strain has shown strong anti-*C. difficile* activity and tolerance to digestive challenges in vitro.
- Other names
- Lactobacillus plantarum GMNL-661
Beyond the preview
Go deeper on Lactiplantibacillus plantarum GMNL-661.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactiplantibacillus plantarum GMNL-661.